Will Fagron stock go up?

According to Danelfin AI, Fagron has today an AI Score of 7/10 (Buy rating), because its probability of beating the market in 3 months (54.84%) is +5.15% vs. the average probability (49.69%) of all European stocks.

Is it a good time to buy, sell, or hold Fagron stock right now?

Fagron has today a Buy rating (AI Score 7/10), according to Danelfin AI. Its probability of beating the market in 3 months (54.84%) is +5.15% vs. the average probability (49.69%) of all European stocks, based on our AI-powered analysis. You can find more details on whether Fagron stock is a good buy .

What is going on with Fagron stock in the last 3 months?

The Fagron stock performance in the last quarter has been +8.59%.

Does Fagron offer dividend payments?

Yes, Fagron stock dividend yield is 1.67%.

What is the current market capitalization of Fagron?

Fagron's market cap is €1.78B, as of 2026-07-02 08:00.

Fagron NV (FAGR.BR) AI Stock Analysis

Advanced Chart

Custom range

Jul 3, 2025

→

Jul 3, 2026

Custom range

Jul 3, 2025

→

Jul 3, 2026

FAGR.BR AI-Powered Stock Analysis

AI Score Explanation

Generating AI Score explanation

We're getting the explanation ready so you can easily understand what's behind the AI Score. This may take a few seconds.

AI Score Explanation

Generating AI Score explanation

We're getting the explanation ready so you can easily understand what's behind the AI Score. This may take a few seconds.

Profitability+1.39%
Profitability and operating efficiency metrics
Earnings Quality+1.09%
Stability and reliability of reported earnings
Volatility+0.91%
How much the stock price tends to fluctuate
Growth+0.88%
Expected pace of revenue and earnings expansion
Sentiment+0.87%
How analysts and the market view the stock
Financial Strength+0.74%
Balance sheet strength and financial resilience
Valuation+0.53%
How the stock is priced relative to its fundamentals

Momentum-1.27%
Direction and strength of recent price movements

FAGR.BR probability advantage of beating the market (3M):

+5.15%

AI Score

Buy

Fagron (FAGR.BR) has an AI Score of 7/10 (Buy) because, according to an overall analysis, it has a probability advantage of +5.15% of beating the market (STOXX 600) in the next 3 months. This advantage is calculated as the difference between the average probability of any European stock (49.69%) and the probability of FAGR.BR (54.84%) of outperforming the market in the next 3 months, as determined by Danelfin AI’s comprehensive analysis.

Average probability of any European stock of beating the market (3M)49.69%
FAGR.BR probability advantage of beating the market (3M)+5.15%
FAGR.BR probability of beating the market (3M)54.84%

FAGR.BR probability advantage of beating the market (3M): +5.15%

The AI-powered overall analysis of Fagron (FAGR.BR) is based on the 33 fundamental, technical, and sentiment features that had the greatest impact on stock performance during the last 24 months (alpha signals). These alpha signals explain the probability advantage of FAGR.BR:

Type	Alpha Signal	Current Value	Value Decile Position	Probability Advantage Impact (3M)
Fundamental	Consolidated Net Income / Loss	45.78M		+0.89%
Fundamental	Diluted EPS	0.62		+0.88%
Sentiment	Fear & Greed Index (CNN)	31	N/A	+0.67%
Technical	Chart Pattern (180d)	figure_131	N/A	-0.64%
Technical	Alpha YTD	0.03%		-0.63%
Technical	Chart Pattern (252d)	figure_25	N/A	+0.54%
Fundamental	Provision For Income Taxes YoY Growth	0.49%		+0.54%
Technical	Chart Pattern (504d)	figure_73	N/A	-0.54%
Fundamental	Fundamentals Impact (Long Tail)	-	N/A	+0.53%
Sentiment	Sentiment Impact (Long Tail)	-	N/A	+0.53%
Technical	Upgrade to unlock			+0.49%
Fundamental	Upgrade to unlock			+0.44%
Fundamental	Upgrade to unlock			+0.38%
Fundamental	Upgrade to unlock			+0.36%
Fundamental	Upgrade to unlock			-0.33%

Rest of Alpha Signals: +1.05%

FAGR.BR probability advantage of beating the market (3M)Total:+5.15%
FAGR.BR AI Score

Significant changes Vs previous day

FAGR.BR Trading Parameters

These suggested trading parameters for a 3-month horizon help improve risk management and decision-making.

Entry:€24.00
Horizon: 3 months
Stop Loss:€XXXXXPro (XXXXXPro) or AI Score < 7/10
Take Profit:€XXXXXPro (XXXXX
Pro
) or AI Score < 7/10

FAGR.BR Proven Buy Signal & Price Forecast

This is the price chart for FAGR.BR from January 1, 2026 until today. The chart indicates, in green, the 93 days when the stock received a Buy/Strong Buy rating (buy signals, AI Score 7 to 10).

Forecast: In the section below, the central dotted line represents the most expected path, while the shaded area indicates the anticipated price range. This is based on previous Buy signals with a 90% confidence level.

Full Track Record

Unlock AI-powered forecast

Closing price (USD)
Buy signals

Forecast:

1 Month
3 Months
6 Months
1 Year

FAGR.BR Average Past Performance & Win Rate

Three months after its 1015 Buy signals since July 2026, FAGR.BR had an average performance of xxxxxx and a xxxxxx Win rate (positive performance).

1015 Past FAGR.BR Buy Signals	1 Month Later	3 Months Later	6 Months Later	1 Year Later
Average Performance				+10.55%
Average Alpha				+2.59%
Win Rate (% Positive Perf.)				80.52%
% Positive Alpha				50.94%

FAGR.BR Frequently Asked Questions

Will Fagron stock go up?
According to Danelfin AI, Fagron has today an AI Score of 7/10 (Buy rating), because its probability of beating the market in 3 months (54.84%) is +5.15% vs. the average probability (49.69%) of all European stocks.
Is it a good time to buy, sell, or hold Fagron stock right now?
What is going on with Fagron stock in the last 3 months?
Does Fagron offer dividend payments?
What is the current market capitalization of Fagron?

Fagron NV Company Profile

Fagron NV (FAGR.BR) is a leading global pharmaceutical compounding company, dedicated to optimizing and innovating personalized medicine worldwide. The company addresses unmet medical needs by providing high-quality, tailor-made pharmaceutical preparations and active pharmaceutical ingredients (APIs) to hospitals, pharmacies, and patients. With a steadfast commitment to research and development, Fagron continuously expands its portfolio of innovative solutions, ensuring adherence to the highest quality and safety standards across its extensive global operations. This focus underscores its mission to improve patient outcomes through customized therapeutic options.

Fagron operates through three distinct yet integrated segments: Fagron Compounding Services, Fagron Trademarks, and Fagron Essentials. Fagron Compounding Services delivers sterile and non-sterile compounded medications, offering precise formulations for individual patient requirements. Fagron Trademarks focuses on developing and marketing branded products and innovative concepts that advance personalized medicine. Complementing these, Fagron Essentials supplies essential raw materials, equipment, and services, forming a comprehensive ecosystem that supports compounding pharmacies in delivering specialized care efficiently.

The company's strategic emphasis on innovation and global expansion drives its leadership in the pharmaceutical compounding market. Fagron consistently invests in R&D to introduce novel solutions and enhance existing offerings, adapting to the dynamic demands of healthcare professionals and patients. By maintaining rigorous quality control and regulatory compliance, Fagron solidifies its position as a trusted partner in the evolving landscape of personalized healthcare. This proactive approach ensures the company remains at the forefront of therapeutic advancements.

Fagron's robust business model and expansive international footprint contribute significantly to its sustainable growth and ability to create long-term value for stakeholders. Its diversified revenue mix, primarily derived from its three core segments, is supported by a go-to-market strategy that effectively combines direct sales channels, robust online platforms, and strategic partnerships with healthcare providers and distributors, ensuring broad accessibility and efficient delivery of its specialized solutions across its global presence, spanning operations and distribution networks in over 35 countries across Europe, North America, South America, and Australia.

Sector:Health Care
Country:Belgium
Industry:
Address:Venecoweg 20A, Nazareth, Nazareth
Employees:4,193
Website:fagron.com

Pros

High switching costs for compounding pharmacy customers

Specialized regulatory navigation expertise across regions

Geographic revenue diversification across multiple continents

Niche market addressing unmet patient needs

Structural demand growth for personalized medicine

Cons

Elevated regulatory compliance costs and scrutiny

Dependency on global active pharmaceutical ingredient supply chain

Reimbursement pressure on compounded medications from payers

Inherent product liability risk from custom formulations

Limited scalability due to individualized production model

Pros

Cons

Company

AI Score

Compare

AGFB.BRAGFA Gevaert NV

GALE.SWGalenica AG

FME.DEFresenius Medical Care AG

FRE.DEFresenius SE & Co KGaA

VBSN.SWIVF Hartmann Holding AG

Company

AI Score

Compare

FAGR.BR Top 10 Industry Stocks

Health Care Providers & Services

	Company	AI Score	Compare
1	LKMNH.E.ISLokman Hekim Engurusag Saglik Turizm Egitim Hizmetleri ve Insaat Taahhut AS
2	TNZTP.E.ISTapdi Oksijen Ozel Saglik ve Egitim Hizmetleri Sanayi Ticaret AS
3	MPARK.E.ISMLP Saglik Hizmetleri AS
4	AEVS.SWAevis Victoria SA
5	LJM1R.RGLatvijas Juras Medicinas Centrs AS
6	ATT.STAttendo AB (publ)
7	IDHC.LIntegrated Diagnostics Holdings PLC
8	UPR.IRUniphar PLC
9	FAGR.BRFagron NV
10	GALE.SWGalenica AG

	Company	AI Score	Compare

FAGR.BR Top 10 Sector Stocks

Health Care

	Company	AI Score	Compare
1	REC.MIRecordati Industria Chimica e Farmaceutica SpA
2	FAE.MCFaes Farma SA
3	ALK B.COALK-Abello A/S
4	ANCR.LAnimalcare Group plc
5	LKMNH.E.ISLokman Hekim Engurusag Saglik Turizm Egitim Hizmetleri ve Insaat Taahhut AS
6	LAB.MCLabiana Health SA
7	TNZTP.E.ISTapdi Oksijen Ozel Saglik ve Egitim Hizmetleri Sanayi Ticaret AS
8	MPARK.E.ISMLP Saglik Hizmetleri AS
9	PRM.MCPrim SA
10	AEVS.SWAevis Victoria SA

	Company	AI Score	Compare

FAGR.BR Stock AI Analysis

Fagron NV

FAGR.BR Stock AI Analysis

Fagron NV

FAGR.BR AI-Powered Stock Analysis

AI Score Explanation

Generating AI Score explanation

AI Score Explanation

Generating AI Score explanation

AI Score Alpha Factors

Alpha Signals: What Drives the AI Score

FAGR.BR probability advantage of beating the market (3M): +5.15%

FAGR.BR Trading Parameters

FAGR.BR Proven Buy Signal & Price Forecast

FAGR.BR Average Past Performance & Win Rate

FAGR.BR Frequently Asked Questions

Will Fagron stock go up?

Is it a good time to buy, sell, or hold Fagron stock right now?

What is going on with Fagron stock in the last 3 months?

Does Fagron offer dividend payments?

What is the current market capitalization of Fagron?

Fagron NV Company Profile

Pros

Cons

Pros

Cons

FAGR.BR Company Profile Summary

FAGR.BR Related Stocks

FAGR.BR Top 10 Industry Stocks

Health Care Providers & Services

FAGR.BR Top 10 Sector Stocks

Health Care

FAGR.BR Stock AI Analysis

Fagron NV

NYSE EURONEXT - EURONEXT BRUSSELS

Will Fagron stock go up?

Is it a good time to buy, sell, or hold Fagron stock right now?

What is going on with Fagron stock in the last 3 months?

Does Fagron offer dividend payments?

What is the current market capitalization of Fagron?

NYSE EURONEXT - EURONEXT BRUSSELS

Pros

Cons

AI Score Explanation

Generating AI Score explanation

FAGR.BR Proven Buy Signal & Price Forecast